肝脏是多种原发性肿瘤组织转移的常见部位。立体定向放射治疗（SBRT）是一种非侵入性治疗技术，对于消融肝部和其他器官的肿瘤有广泛的病人适应症。SBRT涉及一到几个治疗过程中的集中高剂量放射线治疗，导致局部控制率高。近年来，SBRT用于消融有限转移性疾病的应用增加，新出现的前瞻性数据在某些情况下表明了无进展生存率和总体生存率的提高。当对肝转移瘤进行SBRT时，临床医生必须平衡提供消融肿瘤剂量的优先事项，同时尊重周围危险器官（OARs）的剂量约束。运动管理技术对于满足剂量约束、确保低毒性率、维持生活质量以及进行剂量升级至关重要。先进的放射治疗传递方法包括质子治疗、机器人放疗和实时MR引导放疗可能进一步提高肝SBRT的精度。在本文中，我们回顾了有限转移瘤消融的理论基础，肝SBRT的临床结果，肿瘤剂量和OAR的考虑因素以及发展中的策略以改善肝SBRT传递。版权所有©2022 Elsevier Inc.。

The liver is a common site for metastatic spread for various primary tumor histologies. Stereotactic body radiation therapy (SBRT) is a non-invasive treatment technique with broad patient candidacy for the ablation of tumors in the liver and other organs. SBRT involves focused, high-dose radiation therapy delivered in one to several treatments, resulting in high rates of local control. Use of SBRT for ablation of oligometastatic disease has increased in recent years and emerging prospective data have demonstrated improvements in progression free and overall survival in some settings. When delivering SBRT to liver metastases, clinicians must balance the priorities of delivering ablative tumor dosing while respecting dose constraints to surrounding organs at risk (OARs). Motion management techniques are crucial for meeting dose constraints, ensuring low rates of toxicity, maintaining quality of life, and can allow for dose escalation. Advanced radiotherapy delivery approaches including proton therapy, robotic radiotherapy, and real-time MR-guided radiotherapy may further improve the accuracy of liver SBRT. In this article, we review the rationale for oligometastases ablation, the clinical outcomes with liver SBRT, tumor dose and OAR considerations, and evolving strategies to improve liver SBRT delivery.Copyright © 2022 Elsevier Inc. All rights reserved.